Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971357 | 0.88 | F11 (0.37) | RXRAGRIN1GRIN2BNOTUMF11 | |
| SCHEMBL16972185 | 0.88 | RXRA (0.33) | RXRAGRIN1GRIN2BNOTUMF11 | |
| Bromide SCHEMBL16974661 | 0.87 | RXRA (0.32) | RXRAGRIN1GRIN2BNOTUMF11 | |
| SCHEMBL16974697 | 0.86 | NOTUM (0.43) | RXRAGRIN1GRIN2BNOTUMF11 | |
| SCHEMBL30271670 | 0.85 | NOTUM (0.46) | RXRAGRIN1GRIN2BNOTUMP2RX7 | |
| SCHEMBL16971854 | 0.85 | NOTUM (0.46) | RXRAGRIN1GRIN2BNOTUMP2RX7 | |
| SCHEMBL18710656 | 0.84 | RXRA (0.33) | RXRAGRIN1GRIN2BNOTUMF11 | |
| SCHEMBL16972064 | 0.84 | NOTUM (0.45) | RXRAGRIN1GRIN2BNOTUMF11 | |
| SCHEMBL16971962 | 0.84 | RXRA (0.33) | RXRAGRIN1GRIN2BNOTUMF11 | |
| SCHEMBL16971741 | 0.84 | NOTUM (0.35) | RXRAGRIN1GRIN2BNOTUMF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099686-B1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-9777001-B2 | Macrocycles with aromatic P2′ groups as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
| EP-3099686-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015116885-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | RXRA 4183/4885GRIN1 4619/4885GRIN2B 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.